• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[c-MET信号通路及酪氨酸激酶抑制剂在非小细胞肺癌中的研究进展]

[Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].

作者信息

Yu Xiaoqing, Xu Yanjun, Fan Yun

机构信息

Zhejiang Chinese Medical University, Hangzhou 310053, China.

Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2017 Apr 20;20(4):287-292. doi: 10.3779/j.issn.1009-3419.2017.04.10.

DOI:10.3779/j.issn.1009-3419.2017.04.10
PMID:28442019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5999681/
Abstract

c-MET is considered a promising oncogenic driver in non-small cell lung cancer (NSCLC) after the discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). MET activation including gene mutation, amplification and protein overexpression, all of these are potential therapeutic targets and are associated with poor prognosis. Clinical evidence suggests a role for MET activation as both a primary oncogenic driver in subsets of lung cancer, and as a secondary driver of acquired resistance to EGFR-tyrosine kinase inhibitor (TKI). This review focuses on the MET activation in NSCLC and the latest trials of its treatment.

摘要

在表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）被发现之后，c-MET被认为是非小细胞肺癌（NSCLC）中一个有前景的致癌驱动因子。MET激活包括基因突变、扩增和蛋白过表达，所有这些都是潜在的治疗靶点，并且与预后不良相关。临床证据表明，MET激活在肺癌亚组中既是主要致癌驱动因子，也是对EGFR-酪氨酸激酶抑制剂（TKI）获得性耐药的次要驱动因子。本综述聚焦于NSCLC中的MET激活及其治疗的最新试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/342b/5999681/571070afe9d7/zgfazz-20-4-287-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/342b/5999681/571070afe9d7/zgfazz-20-4-287-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/342b/5999681/571070afe9d7/zgfazz-20-4-287-1.jpg

相似文献

1
[Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].[c-MET信号通路及酪氨酸激酶抑制剂在非小细胞肺癌中的研究进展]
Zhongguo Fei Ai Za Zhi. 2017 Apr 20;20(4):287-292. doi: 10.3779/j.issn.1009-3419.2017.04.10.
2
Targeting the MET gene for the treatment of non-small-cell lung cancer.针对 MET 基因治疗非小细胞肺癌。
Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1.
3
[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].肝细胞生长因子/ c-MET抑制剂治疗非小细胞肺癌的研究进展
Zhongguo Fei Ai Za Zhi. 2015 Apr;18(4):240-4. doi: 10.3779/j.issn.1009-3419.2015.04.09.
4
Progress on treatment of MET signaling pathway in non-small cell lung cancer.非小细胞肺癌中 MET 信号通路治疗的进展。
Int J Clin Oncol. 2020 Aug;25(8):1450-1458. doi: 10.1007/s10147-020-01702-0. Epub 2020 May 21.
5
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.人非小细胞肺癌中表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药的当前机制及更新的治疗策略
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
6
Acquired Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.非小细胞肺癌中获得性 Y1248H 和 D1246N 突变介导对 MET 抑制剂的耐药性。
Clin Cancer Res. 2017 Aug 15;23(16):4929-4937. doi: 10.1158/1078-0432.CCR-16-3273. Epub 2017 Apr 10.
7
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.MET基因扩增和MET受体激活不足以预测MET与EGFR抑制剂联合使用对EGFR TKI耐药的非小细胞肺癌细胞的疗效。
PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015.
8
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌在一线酪氨酸激酶抑制剂治疗中出现疾病进展时的优化管理。
Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11.
9
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.针对非小细胞肺癌中 MET 外显子 14 跳跃改变的靶点竞赛：原因、方法、人员、未知和必然。
Lung Cancer. 2017 Jan;103:27-37. doi: 10.1016/j.lungcan.2016.11.011. Epub 2016 Nov 15.
10
The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.c-Met 抑制剂：在对抗晚期非小细胞肺癌的战斗中崭露头角的一类新药。
Curr Pharm Des. 2012;18(37):6155-68. doi: 10.2174/138161212803582478.

引用本文的文献

1
[Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities 
(2025 Version)].《非小细胞肺癌伴MET异常诊治专家共识（2025年版）》
Zhongguo Fei Ai Za Zhi. 2025 Feb 20;28(2):81-94. doi: 10.3779/j.issn.1009-3419.2025.102.01.
2
[Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma].[肺肉瘤样癌的诊断与治疗现状]
Zhongguo Fei Ai Za Zhi. 2018 Dec 20;21(12):902-906. doi: 10.3779/j.issn.1009-3419.2018.12.07.
3
The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis.

本文引用的文献

1
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.针对非小细胞肺癌中 MET 外显子 14 跳跃改变的靶点竞赛：原因、方法、人员、未知和必然。
Lung Cancer. 2017 Jan;103:27-37. doi: 10.1016/j.lungcan.2016.11.011. Epub 2016 Nov 15.
2
Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.中国携带MET外显子14剪接变异的肺腺癌患者对克唑替尼的反应及获得性耐药
Lung Cancer. 2016 Dec;102:118-121. doi: 10.1016/j.lungcan.2016.11.006. Epub 2016 Nov 9.
3
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
替凡替尼治疗实体瘤的疗效与安全性：一项系统评价和荟萃分析。
Oncotarget. 2017 Nov 3;8(68):113153-113162. doi: 10.18632/oncotarget.22615. eCollection 2017 Dec 22.
靶向肺癌中的MET：期望最终会实现吗？
J Thorac Oncol. 2017 Jan;12(1):15-26. doi: 10.1016/j.jtho.2016.10.014. Epub 2016 Oct 26.
4
MEK inhibitors against MET-amplified non-small cell lung cancer.针对MET扩增的非小细胞肺癌的MEK抑制剂
Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.
5
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.卡博替尼在 MET 外显子 14 阳性 NSCLC 伴脑转移患者中的颅内活性。
J Thorac Oncol. 2017 Jan;12(1):152-156. doi: 10.1016/j.jtho.2016.09.127. Epub 2016 Sep 28.
6
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.MET 外显子 14 跳跃型非小细胞肺癌中克唑替尼耐药的预先存在 MET Y1230C 突变的出现
J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.
7
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.298 例携带 MET 外显子 14 跳跃改变的肺癌患者的特征。
J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22.
8
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中 MET 外显子 14 跳跃导致对克唑替尼获得性耐药。
J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.
9
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.通过癌基因重叠分析确定用于定义MET拷贝数驱动的肺腺癌的合适荧光原位杂交（FISH）标准。
J Thorac Oncol. 2016 Aug;11(8):1293-1304. doi: 10.1016/j.jtho.2016.04.033. Epub 2016 Jun 1.
10
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.中国非小细胞肺癌患者 MET 外显子 14 突变的独特特征。
J Thorac Oncol. 2016 Sep;11(9):1503-10. doi: 10.1016/j.jtho.2016.05.016. Epub 2016 May 30.